Peptide candidates for the development of therapeutics and vaccines against β-coronavirus infection

• Published in: Bioengineered Vol. 13; no. 4; pp. 9435 - 9454
• Main Authors: Chourasia, Rounak, Padhi, Srichandan, Phukon, Loreni Chiring, Abedin, Md Minhajul, Sirohi, Ranjana, Singh, Sudhir P, Rai, Amit Kumar
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.04.2022
• Subjects: Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Coronavirus Infections - drug therapy; Coronavirus Infections - prevention & control; COVID-19; Humans; Mutation; peptides; Peptides - genetics; Peptides - therapeutic use; Review; therapeutics; vaccines; Vaccines - therapeutic use; Β-CoV; COVID-19; peptides; therapeutics; Β-CoV; vaccines
• ISSN: 2165-5979; 2165-5987; 2165-5987
• DOI: 10.1080/21655979.2022.2060453

Betacoronaviruses (β-CoVs) have caused major viral outbreaks in the last two decades in the world. The mutation and recombination abilities in β-CoVs resulted in zoonotic diseases in humans. Proteins responsible for viral attachment and replication are highly conserved in β-CoVs. These conserved proteins have been extensively studied as targets for preventing infection and the spread of β-CoVs. Peptides are among the most promising candidates for developing vaccines and therapeutics against viral pathogens. The immunostimulatory and viral inhibitory potential of natural and synthetic peptides has been extensively studied since the SARS-CoV outbreak. Food-derived peptides demonstrating high antiviral activity can be used to develop effective therapeutics against β-CoVs. Specificity, tolerability, and customizability of peptides can be explored to develop potent drugs against β-CoVs. However, the proteolytic susceptibility and low bioavailability of peptides pose challenges for the development of therapeutics. This review illustrates the potential role of peptides in eliciting an adaptive immune response and inhibiting different stages of the β-CoV life cycle. Further, the challenges and future directions associated with developing peptide-based therapeutics and vaccines against existing and future β-CoV pathogens have been discussed.